DOI QR코드

DOI QR Code

Adult Non Hodgkin's Lymphoma Patients: Experience from a Tertiary Care Cancer Centre in North East India

  • Hazarika, Munlima (Department of Medical Oncology, Dr. B Borooah Cancer Institute) ;
  • Iqbal, Asif (Department of Medical Oncology, Dr. B Borooah Cancer Institute) ;
  • Krishnatreya, Manigreeva (Department of Cancer Epidemiology and Biostatistics, Dr. B Borooah Cancer Institute) ;
  • Sharma, Jagannath Dev (Department of Pathology, Dr. B Borooah Cancer Institute) ;
  • Bhuyan, Chidananda (Department of Medical Oncology, Dr. B Borooah Cancer Institute) ;
  • Saikia, Bhargab Jyoti (Department of Medical Oncology, Dr. B Borooah Cancer Institute) ;
  • Roy, Partha Sarathi (Department of Medical Oncology, Dr. B Borooah Cancer Institute) ;
  • Das, Rashmi (Department of Medical Oncology, Dr. B Borooah Cancer Institute) ;
  • Nandy, Pintu (Department of Cancer Epidemiology and Biostatistics, Dr. B Borooah Cancer Institute) ;
  • Kataki, Amal Chandra (Department of Gynecologic Oncology, Dr. B Borooah Cancer Institute)
  • Published : 2015.04.14

Abstract

There is paucity of data on non Hodgkin's lymphoma (NHL) from our population in North-East India. In this retrospective study, patients were consecutively followed-up to see the clinic-pathological pattern of NHL, various responses, and pattern of relapses to first line treatment with chemotherapy. All patients in the present study received standard regimen of cyclophosphamde, doxorubicin, vincristine, prednisolone (CHOP) with or without rituximab (R-CHOP) as per our institutional protocol as first line therapy. Our study has shown that, in our adult population, the majority of NHL cases present with stage II and stage III disease and extra nodal involvement, B-cell lymphomas and diffuse large cell lymphomas being the most common subtypes. International prognostic index was a significant factor for varied responses to treatment. The majority of relapses after complete remission occurred in the first year.

Keywords

Non Hodgkin's lymphoma;adult;responses to treatment;first line chemotherapy

References

  1. Anderson JR, Armitage JO, Weisenburger DD (1998). Epidemiology of the non-Hodgkin's lymphomas: distributions of the major subtypes differ by geographic locations. Ann Oncol, 9, 717-20. https://doi.org/10.1023/A:1008265532487
  2. Balasubramanium G, Saoba S, Sarade M, Pinjare S (2013). Case-control study of risk factors for non-Hodgkin lymphoma in Mumbai, India. Asian Pac J Cancer Prev, 14, 775-80. https://doi.org/10.7314/APJCP.2013.14.2.775
  3. Bofetta P (2011). Epidemiology of adult non-Hodgkin lymphoma. Ann Oncol, 22, 27-31. https://doi.org/10.1093/annonc/mdr287
  4. Dominik D. Alexander, Pamela J, et al (2007). The non-Hodgkin lymphomas: a review of the epidemiologic literature. Int J Cancer, 120, 1-39.
  5. Elis A, Blickstein B, Klein O, et al (2002). Detection of relapse in non- Hodgkin's lymphoma : role of routine follow up studies. Am J Hematol, 69, 41-4. https://doi.org/10.1002/ajh.10017
  6. Eisenhauer EA, Therasse P, Bogaerts J, et al (2009). New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer, 45, 228-47. https://doi.org/10.1016/j.ejca.2008.10.026
  7. Hussain MA, Pati S, Swain S , et al (2012). Pattern and trends of cancer in Odisha, India: a retrospective study. Asian Pac J Cancer Prev, 13, 6333-36. https://doi.org/10.7314/APJCP.2012.13.12.6333
  8. Mertsoylu H, Muallaoglu S, Besen AA, et al (2014). Primary extranodal non-Hodgkin's lymphoma: clinicopathological features, survival and treatment outcome in two cancer centers of southern Turkey. Asian Pac J Cancer Prev, 15, 7207-11. https://doi.org/10.7314/APJCP.2014.15.17.7207
  9. Naresh KN, Srinivas V, Soman CS (2000). Distribution of various subtypes of non-Hodgkin's lymphoma in India: astudy of 2773 lymphomas using REAL and WHO Classifications. Ann Oncol, 11, 63-7.
  10. Padhi S, Paul TR, Challa S, et al (2012). Primary extra nodal non Hodgkin lymphoma: a 5 year retrospective analysis. Asian Pac J Cancer Prev, 13, 4889-95. https://doi.org/10.7314/APJCP.2012.13.10.4889
  11. Sader-Ghorra C, Rassy M, Naderi S, Kourie HR, Kattan J (2014). Type distribution of lymphomas in Lebanon: five-year single institution experience. Asian Pac J Cancer Prev, 15, 5825-8. https://doi.org/10.7314/APJCP.2014.15.14.5825
  12. SallesG,Shipp MA, Coiffier B (1994). Chemotherapy of non-Hodgkin's aggressive lymphomza. Semi Hematol, 31, 46-69.
  13. Schuetz JM, Daley D, Leach S, et al (2013). Non-Hodgkin lymphoma risk and variants in genes controlling lymphocyte development. PLoS One, 8, 75170. https://doi.org/10.1371/journal.pone.0075170
  14. Sengar M, Akhade A, Nair R, et al (2011). A retrospective audit of clinicopathological attributes and treatment outcomes of adolescent and young adult non-Hodgkin lymphomas from a tertiary care center. Indian J Med Paediatr Oncol, 32, 197-203 https://doi.org/10.4103/0971-5851.95140
  15. Smedby KE (2006). Epidemiology and etiology of non-Hodgkin lymphoma a review. Acta Oncol, 45, 258-71 https://doi.org/10.1080/02841860500531682
  16. Zelenetz AD, Abramson JS, Advani RJ et al (2011). Non Hodgkin's lymphomas. J Natl Compr Canc Netw, 9, 484-560
  17. Zhou JY, He LW, Liu J, et al (2014). Comprehensive assessment of associations between ercc2 lys751gln/asp312asn polymorphisms and risk of non-Hodgkin lymphoma. Asian Pac J Cancer Prev, 15, 9347-53. https://doi.org/10.7314/APJCP.2014.15.21.9347